赛的IPO于2026年3月24日开放,筹集了122.6亿卢比,股价在372到392之间. Sai Parenterals' IPO opened on March 24, 2026, raising ₹122.6 crore, with shares priced between ₹372 and ₹392.

赛的IPO于2026年3月24日开放,每股价格为372到392卢比,从包括摩根士丹利 (亚洲) 和科塔克Mahindra生命保险在内的主力投资者那里筹集了122.6亿卢比. Sai Parenterals' IPO opened on March 24, 2026, with a price band of ₹372 to ₹392 per share, raising ₹122.6 crore from anchor investors including Morgan Stanley (Asia) and Kotak Mahindra Life Insurance. 发行价值440亿卢比的股票包括新增股份出售和供销,收益将用于资助产能扩张,研发,债务还款以及营业资本. The ₹440 crore issue includes a fresh share sale and offer for sale, with proceeds to fund capacity expansion, R&D, debt repayment, and working capital. 公司在海德拉巴的总部,报告了25财年163.7亿卢比收入和14.4亿卢布净利,高于23财年的96.7亿盧比和4.37亿卢بی. The company, based in Hyderabad, reported ₹163.7 crore in revenue and ₹14.4 crore in net profit for FY25, up from ₹96.7 crore and ₹4.37 crore in FY23. 公司经营五个设施,出口到受监管的市场,专注于注射药物和口服固体剂型. It operates five facilities, exports to regulated markets, and focuses on injectables and oral solid dosage forms. 首次公开募股将于3月27日结束,预计在3月30日之前进行分配,4月份初步上市. The IPO closes on March 27, with allotment expected by March 30 and a tentative listing in April. 分析师警告高估值倍数,并建议长期投资. Analysts caution about high valuation multiples and recommend long-term investment.